Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by tissue or cell testing to have recurrent or metastatic nasopharyngeal carcinoma of a specific non-keratinizing type (WHO type II or III).
• People aged between 18 and 70 years.
• People with a general health/activity score of 0 or 1 on a standard medical scale, meaning they are fully active or have only minor restrictions on physically strenuous activity.
• People whose cancer has continued to grow or spread after receiving a platinum-based chemotherapy combination.
• People who have received at least one prior course of systemic (whole-body) cancer treatment (disease that worsened during or within 6 months of certain earlier treatments may count as one prior line).
• People whose cancer did not respond to, or stopped responding to, anti-PD-1 immunotherapy (either given alongside other treatments or separately), where that immunotherapy was received for at least 6 weeks.
• People who have at least one tumour that can be measured on scans according to standard criteria (RECIST 1.1).
• People whose side effects from previous cancer treatments have largely settled (to a low level), with some minor ongoing effects such as hair or nail changes being acceptable.
• People whose blood, liver, kidney, and clotting results meet specific minimum thresholds set by the trial (confirm exact values with trial site).
• People with an estimated life expectancy of at least 3 months.
• People who are willing and able to attend study visits, follow the treatment plan, and complete required tests and procedures, and who have signed a consent form.

Who may not be able to join:

• People whose cancer has come back only in a localised area and could potentially be treated with a curative approach such as surgery.
• People who have previously received any of the specific treatment combinations included in this trial's protocol.
• People who have previously been treated with drugs that target a pathway involving proteins called VEGF or VEGFR.
• People who have been diagnosed with or treated for another cancer within the past 5 years, with some exceptions for certain low-risk or early-stage cancers (confirm with trial site).
• People who have had surgery, chemotherapy, radiotherapy, immunotherapy, or any other anti-cancer treatment within 4 weeks before joining (or within 2 weeks for palliative radiotherapy).
• People whose tumour is wrapping around a major blood vessel in the neck (internal carotid artery), or who show signs of tissue breakdown in the nasopharynx area on examination.
• People who have had a significant bleeding event within the 4 weeks before joining, or who have had visible coughing up of fresh blood or blood clots, or who have had repeated positive stool blood test results during screening.
• People with active stomach ulcers or recent stomach/bowel surgery, or a history within 6 months of certain serious digestive complications such as bowel perforation, internal abscess, gastrointestinal bleeding, or fractures caused by disease.
• People with uncontrolled high blood pressure despite medication, significant coronary artery disease, or certain serious heart or blood vessel events (such as heart attack, stroke, or serious heart rhythm problems) within the past 6 months.
• People with a known tendency to bleed abnormally, or who are currently taking blood-thinning or anti-clotting medications unless those medications were stopped at least 10 days before the first dose and blood test results meet the required levels.
• People who have had a serious infection requiring intravenous treatment within 4 weeks before the first dose, or an unexplained high fever within 7 days before the first dose, or an abnormally high white blood cell count.
• People who are known to be allergic or highly sensitive to any of the study drugs or their ingredients.
• People who have difficulty swallowing, persistent nausea or vomiting, chronic diarrhoea, or bowel obstruction that could affect how oral medication is absorbed.
• People who are currently taking immune-suppressing medications or steroid medications above a certain dose within the 2 weeks before the first dose.
• People with an active autoimmune disease or a history of autoimmune conditions likely to return, with limited exceptions (confirm with trial site).
• People who have been hospitalised for a flare-up of a chronic lung condition or other serious breathing problem within 1 month before joining, or who have active tuberculosis or were treated for tuberculosis within the past year.
• People who are HIV positive, have active hepatitis B at a certain level, or have a positive hepatitis C antibody test.
• People who have received a live vaccine within 4 weeks before the first dose, or who expect to receive one during the study.
• People who have a positive pregnancy test or who are currently breastfeeding.
• Women who could become pregnant, or sexually active men, who are unwilling or unable to use medically accepted contraception throughout the study period.
• People with conditions that, in the trial doctor's judgement, could affect their safety or the reliability of the results — such as substance misuse, serious physical or mental illness, or significant personal or family circumstances.

Important: Always verify eligibility with the trial site directly before applying.